Lamivudine treatment for fulminant hepatic failure due to acute exacerbation of chronic hepatitis B infection

Authors

  • S. W. C. Tsang,

    1. Division of Gastroenterology and Hepatology, Department of Medicine and Therapeutics, Prince of Wales Hospital, New Territories, Hong Kong, China
    Search for more papers by this author
  • H. L. Y. Chan,

    1. Division of Gastroenterology and Hepatology, Department of Medicine and Therapeutics, Prince of Wales Hospital, New Territories, Hong Kong, China
    Search for more papers by this author
  • N. W. Y. Leung,

    1. Division of Gastroenterology and Hepatology, Department of Medicine and Therapeutics, Prince of Wales Hospital, New Territories, Hong Kong, China
    Search for more papers by this author
  • T. N. Chau,

    1. Division of Gastroenterology, Department of Medicine, Princess Margaret Hospital, Lai Chi Kok, Hong Kong, China
    Search for more papers by this author
  • S. T. Lai,

    1. Division of Gastroenterology, Department of Medicine, Princess Margaret Hospital, Lai Chi Kok, Hong Kong, China
    Search for more papers by this author
  • F. K. L. Chan,

    1. Division of Gastroenterology and Hepatology, Department of Medicine and Therapeutics, Prince of Wales Hospital, New Territories, Hong Kong, China
    Search for more papers by this author
  • J. J. Y. Sung

    1. Division of Gastroenterology and Hepatology, Department of Medicine and Therapeutics, Prince of Wales Hospital, New Territories, Hong Kong, China
    Search for more papers by this author

Dr S. W. C. Tsang, Department of Medicine, Tseung Kwan O Hospital, 2 Po Ning Lane, Tseung Kwan O, Hong Kong, China. E-mail: swctsang@netvigator.com

Abstract

Background:

Exacerbation of chronic hepatitis B infection can lead to fulminant hepatic failure with a mortality of up to 90%.

Aim:

To evaluate the efficacy of lamivudine in the treatment of this subgroup of patients.

Methods:

Twenty-four patients with exacerbation of chronic hepatitis B infection and fulminant hepatic failure were treated with lamivudine, 100 mg daily. Hepatitis A, C, D and human immunodeficiency virus co-infections and hepatocellular carcinoma were excluded.

Results:

The median age was 53 years (range, 24–77 years) with a male predominance of 20:4. Seventeen patients were hepatitis B e antigen positive. Mean hepatitis B virus DNA was 2079 Meq/mL. Eight patients (33%) survived (group A). Thirteen patients died and three patients received liver transplantation (67%) (group B). Baseline laboratory results were comparable between the two groups, including serum albumin, bilirubin, alanine aminotransferase, prothrombin time and creatinine. Group B patients had significantly more comorbid illnesses at baseline and more complications, including sepsis and renal failure, compared with group A patients. Six out of eight survivors (75%) had full hepatitis B e antigen seroconversion, but this was not sustained in four patients.

Conclusions:

Lamivudine may be useful in treating patients with fulminant hepatic failure due to exacerbation of chronic hepatitis B. Hepatitis B e antigen seroconversion was less durable in this subgroup of patients and long-term therapy may be required.

Ancillary